175 related articles for article (PubMed ID: 16270634)
1. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study.
Visich JE; Zuckerman LA; Butine MD; Gunewardena KA; Wild R; Morton KM; Reynolds TC
Thromb Haemost; 2005 Oct; 94(4):802-7. PubMed ID: 16270634
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers.
Reynolds TC; Butine MD; Visich JE; Gunewardena KA; MacMahon M; Pederson S; Bishop PD; Morton KM
J Thromb Haemost; 2005 May; 3(5):922-8. PubMed ID: 15869585
[TBL] [Abstract][Full Text] [Related]
3. Preclinical safety and pharmacokinetics of recombinant human factor XIII.
Ponce RA; Visich JE; Heffernan JK; Lewis KB; Pederson S; Lebel E; Andrews-Jones L; Elliott G; Palmer TE; Rogge MC
Toxicol Pathol; 2005; 33(4):495-506. PubMed ID: 16036868
[TBL] [Abstract][Full Text] [Related]
4. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report.
Levy JH; Gill R; Nussmeier NA; Olsen PS; Andersen HF; Booth FV; Jespersen CM
Thromb Haemost; 2009 Oct; 102(4):765-71. PubMed ID: 19806264
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients.
Williams M; Will A; Stenmo C; Rosholm A; Tehranchi R
Haemophilia; 2014 Jan; 20(1):99-105. PubMed ID: 23834599
[TBL] [Abstract][Full Text] [Related]
6. Sushi domains in the B subunit of factor XIII responsible for oligomer assembly.
Souri M; Kaetsu H; Ichinose A
Biochemistry; 2008 Aug; 47(33):8656-64. PubMed ID: 18652485
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study.
Brackmann HH; Egbring R; Ferster A; Fondu P; Girardel JM; Kreuz W; Masure R; Miloszewski K; Stibbe J; Zimmermann R
Thromb Haemost; 1995 Aug; 74(2):622-5. PubMed ID: 8584996
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
Lovejoy AE; Reynolds TC; Visich JE; Butine MD; Young G; Belvedere MA; Blain RC; Pederson SM; Ishak LM; Nugent DJ
Blood; 2006 Jul; 108(1):57-62. PubMed ID: 16556896
[TBL] [Abstract][Full Text] [Related]
9. Safety of recombinant human factor XIII in a cynomolgus monkey model of extracorporeal blood circulation.
Ponce R; Armstrong K; Andrews K; Hensler J; Waggie K; Heffernan J; Reynolds T; Rogge M
Toxicol Pathol; 2005; 33(6):702-10. PubMed ID: 16243775
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.
Kerlin BA; Inbal A; Will A; Williams M; Garly ML; Jacobsen L; Kearney SL
J Thromb Haemost; 2017 Aug; 15(8):1601-1606. PubMed ID: 28581691
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
Kerlin B; Brand B; Inbal A; Halimeh S; Nugent D; Lundblad M; Tehranchi R
J Thromb Haemost; 2014 Dec; 12(12):2038-43. PubMed ID: 25263390
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial.
Karkouti K; von Heymann C; Jespersen CM; Korte W; Levy JH; Ranucci M; Sellke FW; Song HK
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):927-39. PubMed ID: 23820174
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency.
Brand-Staufer B; Carcao M; Kerlin BA; Will A; Williams M; Tornøe CW; Sandberg Lundblad M; Nugent D
Haemophilia; 2015 May; 21(3):380-385. PubMed ID: 25643920
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
16. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.
Carcao M; Altisent C; Castaman G; Fukutake K; Kerlin BA; Kessler C; Lassila R; Nugent D; Oldenburg J; Garly ML; Rosholm A; Inbal A
Thromb Haemost; 2018 Mar; 118(3):451-460. PubMed ID: 29448295
[TBL] [Abstract][Full Text] [Related]
17. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin.
Siebenlist KR; Meh DA; Mosesson MW
Thromb Haemost; 2001 Nov; 86(5):1221-8. PubMed ID: 11816711
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
19. Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency.
Cojutti PG; Zanon E; Pasca S; Pea F;
Clin Pharmacokinet; 2022 Apr; 61(4):505-513. PubMed ID: 34718987
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
